Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN8237 (alisertib) with rituximab and vincristine in relapsed or refractory aggressive B-cell lymphoma
2011-000609-32Phase 2Unknown
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of alisertib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, transformed (t-FL), aggressive B-cell lymphoma and 2 more, sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Primary endpoints Part 1. Status: unknown.
02
Drugs
alisertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma, transformed (t-FL)aggressive B-cell lymphomamantle cell lymphoma (MCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2011-000609-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000609-32.